Using patient tumor cells to test lung cancer treatment response
Part of Cancer, Lungs & breathing clinical trials.
This study looks at lung cancer samples you provide to see how tumor cells respond to treatment. It may help researchers find better ways to choose treatments for lung cancer by testing response in a lab model.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older).
- You have been told you have lung cancer or a lung mass/lymph node swelling that will need standard treatment or surgery.
- You can sign an informed consent form before any study tasks.
- You are able and willing to fill out questionnaires about smoking and alcohol history and your work/environment exposures.
- Your treating doctor believes you can complete the study steps.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at preserved tissue samples from people with lung cancer to understand why some tumors don't respond to immunotherapy drugs like PD-1/PD-L1 inhibitors. The goal is to find patterns that could help predict treatment success.
This trial grows “organoids” (mini tumor models) from your lung cancer tissue to see which drug responses are most likely. It may help match future treatments to how your tumor behaves in the lab.
This study collects lung cancer tissue samples from patients undergoing surgery to create laboratory models that help researchers test new treatments. Your participation helps advance personalized cancer medicine for future patients.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This trial tests a new way to choose your next treatment by growing a mini version of your tumor (an organoid) in a lab and seeing which drugs kill it best. It is for people with drug-resistant non-small cell lung cancer who have already tried at least two standard treatments.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Hear when a new Lung Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.